Overview
- Editors:
-
-
Ross G. Cameron
-
Department of Pathology Division of Experimental Pathology, University of Toronto, Toronto, Canada
-
George Feuer
-
Department of Clinical Biochemistry Banting Institute, University of Toronto, Toronto, Canada
-
Felix A. Iglesia
-
Parke-Davis Pharmaceutical Research Division Department of Pathology and Experimental Toxicology, Warner Lambert Company, Ann Arbor, USA
Access this book
Other ways to access
About this book
The advances in science and medicine we are now experiencing are unprec edented and exciting. Life expectancy is prolonged, and quality of life is much improved. We learn of fabulous new discoveries made at the bench or the bedside every week. Many diseases have been totally eliminated, others can be significantly improved by new therapeutic formulations. Much of the success can be attributed to a better understanding of disease processes and the specific targeting of new and more effective medications. As is the case in many areas of successful human endeavour, there can be a downside. In the case of drugs and chemicals it is their adverse effects which are of concern. Of course, every effort is made to devise medications that are safe, and the need to elucidate and understand mechanisms are crucial, yet adverse effects remain a problem. They can be unpredictable and diverse. Drugs have been shown to induce virtually the whole gamut of human liver pathology from acute fulminant hepatitis to chronic active hepatitis to cirrho sis and even malignancy. Hence the possibility of adverse drug effects must be considered in the differential diagnosis of many patients with liver disease. This is well recognized and is very important; indeed, removal of the offending agent can often lead to reversal of the adverse effect. This is an area of hepatology where we can really make a difference.
Similar content being viewed by others
Table of contents (26 chapters)
-
- H. J. Zimmerman, K. G. Ishak
Pages 457-476
-
- R. G. Cameron, F. A. de la Iglesia, G. Feuer
Pages 477-513
-
- M. J. Zuckerman, S. Anuras
Pages 515-542
-
- H. I. Zimmerman, K. G. Ishak
Pages 543-579
-
- R. J. Fingerote, G. A. Levy
Pages 581-609
-
-
- H. J. Zimmerman, K. G. Ishak
Pages 637-662
-
Back Matter
Pages 663-683
Editors and Affiliations
-
Department of Pathology Division of Experimental Pathology, University of Toronto, Toronto, Canada
Ross G. Cameron
-
Department of Clinical Biochemistry Banting Institute, University of Toronto, Toronto, Canada
George Feuer
-
Parke-Davis Pharmaceutical Research Division Department of Pathology and Experimental Toxicology, Warner Lambert Company, Ann Arbor, USA
Felix A. Iglesia